FENC - Company ID 0001211583
FENNEC PHARMACEUTICALS INC. trades as FENC. In its fiscal 2025 annual report the company posted revenue of $44.64M, down 6.1% from the prior year and net income of -$9.74B. This page tracks FENNEC PHARMACEUTICALS INC. through 792 SEC filings, with financial statements and metrics updated as new reports are filed.
Research snapshot
Updated
With latest filings
Data parsed from SEC EDGAR XBRL filings. See the full market cap rankings.
Next research step
Net profit margin compressed from -9054.5% to -21820.3% over the same period - every figure below comes from the company's audited annual filings.
Dig into the full income statement, balance sheet, and cash flow statement with annual and quarterly views.
| Filing | Type | Filed |
|---|---|---|
| Major company event | 8-K | 2026-05-22 |
| Major company event | 8-K | 2026-05-18 |
| SCHEDULE 13G/A | - | 2026-05-15 |
| SCHEDULE 13G/A | - | 2026-05-14 |
| Quarterly report | 10-Q | 2026-05-14 |
| Insider trade | 4 | 2026-05-12 |
| Insider sale notice | 144 | 2026-05-11 |
| Insider trade | 4 | 2026-05-01 |
The largest companies sharing FENNEC PHARMACEUTICALS INC.'s SEC industry classification (biological products, (no diagnostic substances)).
FENNEC PHARMACEUTICALS INC. reported revenue of $44.64M for fiscal year 2025, a decrease of 6.1% year over year.
In its latest fiscal year FENNEC PHARMACEUTICALS INC. reported a net loss of $9.74B.